On Monday, Hikma announced a partnership with Celltrion to market YUFLYMA (CT-P17) in the Middle East and North Africa. CT-P17 is a high-concentration, low-volume and citrate-free adalimumab biosimilar, indicated for the treatment of a number of conditions including rheumatoid arthritis, ankylosing spondylitis, and Crohn's disease. According to Hikma, CT-P17 provides pain-reducing features and causes less pain upon injection. The partnership agreement would give Hikma exclusive rights to commercialize YUFLYMA in all of its Middle East/North Africa markets.
PRESS RELEASE
21 July 2022
Hikma And Celltrion Announce Collaboration To Market Adalimumab Biosimilar YUFLYMA In Middle East And North Africa
Goodwin Procter LLP
Contributor
At Goodwin, we partner with our clients to practice law with integrity, ingenuity, agility, and ambition. Our 1,600 lawyers across the United States, Europe, and Asia excel at complex transactions, high-stakes litigation and world-class advisory services in the technology, life sciences, real estate, private equity, and financial industries. Our unique combination of deep experience serving both the innovators and investors in a rapidly changing, technology-driven economy sets us apart.
On Monday, Hikma announced a partnership with Celltrion to market YUFLYMA (CT-P17) in the Middle East and North Africa. CT-P17 is a high-concentration...